Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

232 results about "Primary motor neuron" patented technology

Upper motor neurons. Upper motor neurons originate in the motor cortex located in the precentral gyrus. The cells that make up the primary motor cortex are Betz cells, which are a type of pyramidal cell. The axons of these cells descend from the cortex to form the corticospinal tract.

Spinal epidural ventral side double-wing-shaped stimulating electrode and motion function reconstruction system

The invention belongs to the technical field of medical instruments, and particularly relates to a spinal epidural ventral side double-wing-shaped stimulation electrode and motion function reconstruction system, the spinal epidural ventral side double-wing-shaped stimulation electrode and motion function reconstruction system comprises two wing panels, each wing panel comprises a flexible substrate, the flexible substrate is provided with two bifurcated preset-curvature double-wing structures; the electrode contact array is integrated on the flexible polar plate through a bonding pad; according to the double-wing-shaped flexible substrate, through a double-wing structure with a preset curvature, after being unfolded under the driving of a nickel-titanium alloy framework, the double-wing-shaped flexible substrate accurately covers a spinal cord ventral side and double-side anterior angle motor neuron pool, and the problem that a traditional single-piece / rod-shaped electrode can only cover a back side sensing area and cannot cover a back side sensing area is solved. The ventral motor neuron group cannot be directly activated; a stimulation target spot is transferred to a ventral functional core area from a dorsal non-target area for the first time, and the anatomical suitability bottleneck of motor function reconstruction is solved.
Owner:JILIN UNIVERSITY

Application of protein polymer in treatment of gradual freezing

The invention belongs to the technical field of biology, and discloses an application of a protein polymer in treatment of gradual freezing. The protein polymer is obtained by stimulating mesenchymal stem cells and separating and purifying split mesenchymal stem cells. In SOD1 mutant mouse experiments, the protein polymer can significantly increase the number of anterior spinal horn motor neurons, improve muscular atrophy, improve the motility of mice and prolong the lifetime of the mice; in a clinical experiment, the protein polymer shows the effect of blocking the course of the asymptotheca, the concentration of the TDP-43 protein in cerebrospinal fluid can be reduced, and the concentration of the TDP-43 protein in serum can be increased.
Owner:DARWIN BIOTECHNOLOGY (HUBEI) CO LTD

Methods of use of islet cells

Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. Described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.
Owner:CEDARS SINAI MEDICAL CENT

ShRNA for knocking down BST2 gene expression, recombinant vector and application

The invention belongs to the technical field of gene engineering, and provides shRNA (short hairpin Ribonucleic Acid) for knocking down BST2 gene expression, a recombinant vector and application of the shRNA, and the shRNA comprises Bst2-shRNA-1 or Bst2-shRNA-2; the Bst2-shRNA-1 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO. 1 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO. 2; the Bst2-shRNA-2 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO. 3 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO. 4. The shRNA disclosed by the invention plays an important role in inhibiting non-infectious aseptic inflammation, can effectively delay the ALS attack time and protect motor neurons, has a very good application prospect, and also provides a direction and a technical basis for searching, researching and developing new therapeutic drugs for treating ALS.
Owner:CHIFENG MUNICIPAL HOSPITAL

Systems, methods, and techniques for safely controlling devices using eye gaze control

Methods, systems, and techniques for controlling actuators by using eye gaze technology such as in a wheelchair or bed, are provided. Example embodiments provide an Eye Gaze Actuator Control System (“EGACS”) which enables people with advanced motor neuron diseases or disabilities like amyotrophic lateral sclerosis or muscular dystrophy to use eye gaze technologies to control their actuators that control seating, bed positioning, and movement of motor-controlled devices. In one embodiment, the example EGACS comprises a display device, eye gaze sensor, eye gaze control application, and device interface(s) to one or more other devices that control aspects of a powered wheelchair, bed, vehicle, or other device. These components cooperate to control the powered wheelchair, bed, or vehicle using eye gaze technology as opposed to by manual control.
Owner:BEAVERS JAY CURTIS

Use of simulated weightlessness culture method and / or mechanically sensitive ion channel inhibitor for in vitro culture of motor neurons

PendingCN119220495ACulture processNervous system cellsMechanosensitive ion channelPrimary motor neuron
The present application relates to the use of a simulated weightlessness culture method and / or a mechanically sensitive ion channel inhibitor for in vitro culture of motor neurons; in addition, the invention also relates to a method for culturing motor neurons in vitro. The method comprises the step of culturing cells by using a simulated weightlessness culture method and / or a mechanical sensitive ion channel inhibitor as an auxiliary means.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH

Methods for reducing Ataxin-2 expression

Provided herein are methods for decreasing Ataxin-2 mRNA expression. Such methods are useful to ameliorate symptoms of Ataxin-2 associated diseases. Such Ataxin-2 associated diseases include amyotrophic lateral sclerosis (ALS). Such symptoms include loss of motor function, reduced CMAP amplitude, denervation, and loss of motor neurons.
Owner:IONIS PHARMACEUTICALS INC

Co-culture method and model for motor neurons and myotubular cells and application of co-culture method and model

The invention provides a motor neuron and myotubular cell co-culture method and model and application thereof. The motor neuron and myotubular cell co-culture method comprises the steps that motor neuron is cultured to form a neural network, and a motor neuron culture layer with the formed neural network is obtained; culturing myoblasts, inducing differentiation to form fine myotube cells, adding a mitosis inhibitor, and digesting and separating to obtain the fine myotube cells; and inoculating fine myotubular cells to the motor neuron culture layer with the formed neural network, and co-culturing. The co-culture method disclosed by the invention overcomes the limitation of a traditional nerve cell and muscle cell co-culture method, and has the advantages of simplicity, convenience, high efficiency, stability and the like. The method not only provides an effective experimental tool for related basic research of neuromuscular joint formation, physiological functions and the like, but also has wide application prospects in the fields of neuromuscular disease research, drug screening, toxicological research, gene therapy and the like.
Owner:ZHEJIANG UNIV +1

Medicament for treating diseases related to motor neuron injury

ActiveCN119139498AImprove motor functionNervous disorderMuscular disorderDiseasePharmacy medicine
The invention relates to a medicine for treating diseases related to motor neuron injury. The medicine comprises circular RNA (Ribonucleic Acid) with circBank ID (Identity) being hsacircPTPRN2018 and an applicable medicine carrier, the invention also relates to application of the circular RNA in preparation of medicines for treating diseases related to motor neuron injury.
Owner:WUHAN HONGCHEN INNOVATION BIOTECHNOLOGY CO LTD

Medium composition for culturing neuromuscular organoid and method for producing neuromuscular organoid

The present invention relates to a medium composition for culturing a neuromuscular organoid, a method for producing a neuromuscular organoid, etc. The neuromuscular organoid of the present invention is cultured in a medium containing a composition comprising a sonic hedgehog signaling agonist as an effective ingredient, thereby promoting not only a process of differentiating neurons constituting the neuromuscular organoid into motor neurons, but also the development and maturation of muscle fibers. The interaction between motor neurons and muscle tissues through a neuromuscular junction is essential for the cause and treatment of degenerative neuromuscular diseases, and thus, the neuromuscular organoid of the present invention can be used as a model of neuromuscular diseases (specifically, a degenerative neuromuscular disease model). Therefore, the present invention is expected to be applicable to research on the mechanism of nerve and muscle diseases and drug screening.
Owner:ANIMUSCURE INC

Application of tanshinone IIA in preparation of brachial plexus injury treatment medicine

The invention discloses application of tanshinone IIA in preparation of a medicine for treating brachial plexus injury. According to the invention, tanshinone IIA is adopted to treat a brachial plexus root avulsion injury-replantation rat model, the treatment effect of tanshinone IIA on brachial plexus root avulsion injury is researched and confirmed, and the molecular mechanism is discussed. Results show that after brachial plexus injury causes rat motor function damage and muscle atrophy, after the tanshinone IIA is administered, survival of BPA rat motor neurons and axon regeneration can be effectively promoted, then recovery of the motor function is promoted, and meanwhile expression of Rac1 / Cdc42 and JNK / c-Jun pathways is up-regulated. The result shows that the tanshinone IIA can promote the recovery of nerve and motor functions after BPA injury by up-regulating Rac1 / Cdc42 and JNK / c-Jun pathways.
Owner:DONGGUAN GUANGZHOU UNIV OF TRADITIONAL CHINESE MEDICINE RES INST

Formulations and uses of rock2 inhibitors for als

Provided herein, inter alia, pharmaceutical formulations for oral administration of ROCK2 inhibitors (e.g., compound A). Also provided are methods for treating a neurodegenerative disease characterized by the degeneration of motor neurons, and particularly amyotrophic lateral sclerosis (ALS), the method comprising administering to the subject in need thereof a therapeutically effective amount of a ROCK2 inhibitor.
Owner:GRAVITON BIOSCIENCE BV

System and Method Configured for Analysing Acoustic Parameters of Speech to Detect, Diagnose, Predict and / or Monitor Progression of a Condition, Disorder or Disease

The present invention relates to a system and method configured for analysing acoustic parameters of speech to detect, diagnose, predict and / or monitor progression of a condition, disorder, or disease, and more particularly, any of paediatric and adult neurological and central nervous system conditions including but not limited to low back pain, multiple sclerosis, stroke, seizures, Alzheimer's disease, Parkinson's disease, dementia, motor neuron disease, muscular atrophy, acquired brain injury, cancers involving neurological deficits, paediatric developmental conditions and rare genetic disorders such as spinal muscular atrophy. The system and method extracts a first formant data set from words spoken by an individual and uses these to classify the vowels in the words on a first computing device, such as a mobile smart phone equipped with a microphone into which an individual speaks. The system stores at least some of these frequencies for the vowel formants in a second formant data set as a recorded file and provides the second formant data set as input to acoustic metrics to generate score data from which an assessment is made to determine the articulation level of the vowels in the words spoken by the individual, allowing allow for detection, diagnosis, prediction and / or monitoring progression of the condition, disorder, or disease.
Owner:BEATS MEDICAL

Medicament for treating disease related to motor neuron injury

Provided is a medicament for treating a disease related to motor neuron injury. The medicament comprises: a circular RNA having a circBank ID of hsa_circPTPRN2_018, and a proper diagnosis module and a drug carrier. Also provided is use of a circular RNA in preparing a medicament for diagnosing and treating a disease related to motor neuron injury.
Owner:WUHAN HONGCHEN INNOVATION BIOTECHNOLOGY CO LTD

Method for detecting human motor neuron survival gene SMN

The invention discloses a method for detecting a human motor neuron survival gene SMN and a kit for detecting the human motor neuron survival gene SMN. The invention relates to a calculation method capable of better performing copy number variation of a human motor neuron survival gene SMN and application of the calculation method in accurate and quantitative detection of the high copy number of the human motor neuron survival gene SMN. By adopting the method disclosed by the invention, the copy number variation of SMN1 exon 7 and exon 8, SMN2 exon 7 and exon 8, SMN1 tiny variation, composite heterozygous mutation and silence carriers can be simultaneously detected in one tube.
Owner:品峰(北京)医疗器械有限公司 +1

Method for inducing differentiation into neuromuscular junctions

In a method for inducing differentiation into neuromuscular junctions according to the present disclosure, the neuromuscular junctions are induced by: preculturing human pluripotent stem cells in a medium containing activin, bFGF, a WNT signal inhibitor, a BMP signal inhibitor, and a ROCK signal inhibitor; then culturing the stem cells in a medium containing bFGF, a ROCK signal inhibitor, a WNT signal activator, and a TGFβ signal inhibitor to differentiate into neuromesodermal cells; culturing the neuromesodermal cells in a medium containing a BMP signal inhibitor, a TGFβ signal inhibitor, a retinoic acid activator, and an SHH signal activator to differentiate into skeletal muscle progenitor cells and spinal motor neuron progenitor cells in the same culture dish; and culturing these progenitor cells in a medium for cell maturation containing BDNF, GDNF, AA, and dbcAMP.
Owner:EDUCATIONAL FOUND OF OSAKA MEDICAL & PHARMA UNIV

Regulatory element for cell type specific expression of genes in spinal motor neurons

PendingUS20250135029A1Organic active ingredientsVectorsCholinergic cellsPrimary motor neuron
The subject matter described here relates to an enhancer specific to a subset of cholinergic neurons, that can control gene expression in a highly neuron-specific manner, wherein the enhancer is compatible with AAVs packaging and can induce gene expression or knockdown in cholinergic neurons in both post-natal and adult subjects.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Method and culture medium formulation which can be used to obtain motor neurons from pluripotent stem cell-derived neuromesodermal stem cells

A culture medium and a method using the said medium for obtaining motor neuron cells from human pluripotent stem cell-derived neuromesodermal stem cells (NMSCs) are provided. Furthermore, the present invention relates to obtaining motor neuron cells which can be used in research and clinical applications thanks to the said culture medium and method.
Owner:YEDITEPE UNIVERSITESI

Peptide biomarker for neurological disease, in particular motor neuron disease

The present invention relates to a splice variant of a CERT1 protein that acts as a biomarker for a TDP-43 pathology, in particular motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), but also other neurological diseases, such as Alzheimer's disease. In particular, the present invention relates to methods for identifying a splice variant of CERT1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and / or reduced TDP-43 function in a subject and to methods for predicting whether a therapy is likely to be successful. Also claimed are antibodies binding to the CERT1 splice variant and kits comprising the antibody.
Owner:F HOFFMANN LA ROCHE & CO AG +1

Anti-synaptotagmin 2 antibody

PCT designated stage expiredWO2025084395A1FungiNervous disorderSynapsePrimary motor neuron
The present invention addresses the problem of providing an antibody which excels at binding to the intravesicular domain of synaptotagmin 2. Provided is a synaptotagmin 2 antibody capable of efficiently targeting a desired substance toward a motor neuron synapse.
Owner:JIKSAK BIOENGINEERING INC

Analysis method for storage of single vesicles in ventral spinal cord motor neuron-like organs induced and differentiated by iPSC technology

The invention discloses an analysis method for storage of single vesicles in ventral spinal cord motor neuron-like organs induced and differentiated by an iPSC technology. The method sequentially comprises the steps of construction of an acetylcholine nano microelectrode sensor interface, recovery and culture of human pluripotent stem cells, directional differentiation of spinal cord movement organs and storage and detection of single vesicle acetylcholine. A new thought and a new method are provided for monitoring the level of acetylcholine stored in the single vesicles at the single cell level, and the method has important theoretical significance and wide practical value in research of pathogenesis of diseases, drug screening and the like in the field of neuroscience.
Owner:NANJING MEDICAL UNIV

Composition for the prevention or treatment of neurodegenerative or motor neuron diseases comprising halofuginone as an active ingredient

PendingUS20240390377A1Organic active ingredientsNervous disorderNeuron cell deathNervous system
The present invention relates to a composition for the prevention or treatment of neurodegenerative or motor neuron diseases comprising halofuginone as an active ingredient. Specifically, in Amyotrophic Lateral Sclerosis (ALS) cell and animal models, halofuginone inhibits fibrosis induced by elevated TGF-β, enhances skeletal muscle formation, improves joint contracture, and exhibits dual effects of suppressing inflammatory responses and neuronal cell death in the central nervous system, and then, halofuginone leads to the delay in the progression of ALS symptoms, improvement in performance capabilities, and extension of survival duration. Consequently, halofuginone can be usefully utilized as an active ingredient in a composition for the prevention or treatment of neurodegenerative or motor neuron diseases including ALS.
Owner:SEOUL NAT UNIV HOSPITAL +1

C-ABL tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and / or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1

Modeling TDP-43 proteinopathy

To provide modeling of TDP-43 proteinopathy.SOLUTION: Disclosed herein is the discovery that neither nuclear localization signal (NLS) nor prion-like domain (PLD) of TDP-43 is necessary for embryotic stem cell culture and differentiation into motor neurons in vitro. The capability of ES cells to express TDP-43 variants and differentiate into neurons exhibiting an ALS-like phenotype (the TDP-43 variants redistribute to and aggregate in the cytoplasm, and fail to regulate cryptic exon splicing) allows these cells to act as a model of TDP-43 proteinopathy for the testing of candidate therapeutic agents that may resolve such proteinopathy. Further, these ES cells may be used for successfully generating a non-human animal such as a mouse exhibiting characteristic symptoms of ALS, for use in the search of candidate agents useful for the treatment of TDP-43 proteinopathy.SELECTED DRAWING: None
Owner:REGENERON PHARMACEUTICALS INC